Apellis Eye Drug Safety Review Reveals Link to Rare Blindness Cases

Five elderly patients have experienced blindness in one eye after receiving injections of Apellis Pharmaceuticals' newly approved eye disease treatment, Syfovre. The cause of this severe side effect, a type of eye inflammation, is still unknown. Apellis conducted its own internal review, finding fewer cases of the severe eye inflammation, but maintains that the rate of occurrence remains very rare and there is no evidence linking the drug or its manufacturing to the side effect.